- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00071110
Electroacupuncture for Major Depression
Electroacupuncture for Major Depression: A Pilot Study
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Major depression is a common and serious mental illness. It is associated with a markedly lower quality of life, significant functional impairment, and premature death due to suicide or comorbid physical illness. Over the past 50 years, effective and safe treatments for major depression have been developed, including antidepressant pharmacotherapy, psychotherapy, and electroconvulsive therapy. However, many Americans who suffer from a depressive disorder either do not elect to receive one of these conventional treatments or do not complete an adequate course of treatment. A growing number of Americans with depression are choosing to be treated with complementary and alternative therapies. Acupuncture, in particular, is increasingly being used to treat depression even though only limited data support its safety and efficacy.
This study will use a randomized parallel-group design to compare the safety, efficacy, and tolerability of electroacupuncture (EA) and sham electroacupuncture (SA) for the treatment of major depression. Over a 15-month period, 60 adult outpatients with a major depressive disorder of mild or moderate severity (as defined by the DSM-IV) will be randomized to either 12 sessions of EA or SA to be provided over 6 weeks. Safety and symptomatic improvement (as measured with the Hamilton Rating Scale for Depression [HRSD]) will constitute the primary outcome measures. Tolerability and functional improvement will constitute secondary outcome measures.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15213
- UPMC Shadyside, Center for Complementary Medicine
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Meet SCID criteria for a Major Depressive Disorder (Single or Recurrent) with a current major depressive episode of mild or moderate severity
- Significant symptoms of depression (HRSD > 14)
- Ability to communicate in English
- Give informed consent in accordance with local IRB regulations
Exclusion Criteria:
- Personal physician's recommendation against enrollment because the patient is physically unstable or for other reasons
- Having been treated with acupuncture for any condition
- History of seizure disorder or significant risk factors for a seizure disorder (e.g., history of brain trauma, recent stroke, or brain tumor)
- Need to remain on antidepressant or other psychotropic medications
- Absence of depressive symptoms severe enough (i.e., HRSD < 14) at the baseline assessments
- Significant cognitive impairment, as assessed by a total score on the MMSE < 25. A recommendation for referral to a neurologist or a psychiatrist will be made to the patient in these cases.
- Chronic major depression (i.e, duration of 2 years or longer) A recommendation for referral to a psychiatrist will be made in these cases.
- Major depressive episode severe or severe with psychotic features (as per DSM-IV/SCID) or with acutely suicidality. A recommendation for psychiatric referral will be made in these cases. Bipolar disorder, psychotic features, or a psychotic disorder (specifically: schizophrenia, delusional disorder, or schizoaffective disorder). A recommendation for psychiatric referral will be made in these cases.
- Met criteria for a diagnosis of alcohol substance abuse or dependence within the past six months. A recommendation for referral to a mental health professional will be made in these cases.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 1
Electroacupuncture (EA).
|
For subjects randomized to EA, needles were placed at points GV-20-on the crown of the head and yin tang-on the midline of the forehead roughly at the glabella and treated with electrical stimulation.
30 mm x 0.22 mm sterile stainless steel needles were placed obliquely to a depth of approximately 10 mm and were connected to face-microelectrodes which were connected to the Pantheon Research PENS-Electrostimulator. Electricity was provided at a frequency of 2 Hz and set to a voltage which resulted in the perception of a mild intensity stimulation.
|
Placebo Comparator: 2
Sham
|
For subjects randomized to SA, two needles were placed laterally on the scalp, 3 cuns superior to the temporal attachment of the helix of the ear.
This point was selected as it does not correspond to any specific meridian acupuncture point.
A disabled electrical cable was connected to the needles and the electrostimulator, with light blinking at 2 Hz but no electrical stimulation provided.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Antidepressant Response, Defined as a Hamilton Depression Rating Scale Score Relative Decrease of 50 % or More and a Final Score < 10
Time Frame: Change from Baseline to Post-Intervention Endpoint
|
Number of participants whose Hamilton Depression Rating Scale score decreased at least 50% and had a final score less than 10.
Minimum score = 0 (best).
Maximum score = 52 (worst).
The 17 item scale assesses depression symptoms, including Depressed Mood, Feelings of Guilt, Suicidal Ideation, Insomnia, Anxiety, Weight Change, and Insight.
|
Change from Baseline to Post-Intervention Endpoint
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Functioning and Health-related Quality of Life as Rated by the Medical Outcomes Survey-Version 1 (MOS-36) Physical Component Score (MOSPCS)
Time Frame: Mean Change from Baseline to Post-Intervention Endpoint
|
Mean change in scores on the Medical Outcomes Survey-Version 1 (MOS-36) PHYSICAL Component Score (MOSPCS) from baseline to post-intervention across treatment group.
Minimum Score = 0 (worse); Maximum Score = 100 (better), Normed to be at 50 on a control population.
Positive Mean Change scores indicate improvement (an increase in scale score/better).
|
Mean Change from Baseline to Post-Intervention Endpoint
|
Change in Functioning and Health-related Quality of Life as Rated by the Medical Outcomes Survey-Version 1 (MOS-36) Mental Component Score (MOSMCS)
Time Frame: Mean Change from Baseline to Post-Intervention Endpoint
|
Mean change in scores on the Medical Outcomes Survey-Version 1 (MOS-36) Mental Component Score (MOSMCS) from baseline to post-intervention across treatment group.
Minimum Score = 0 (worse); Maximum Score = 100 (better) , Normed to be at 50 on a control population.
Positive Mean Change scores indicate improvement (an increase in scale score).
|
Mean Change from Baseline to Post-Intervention Endpoint
|
Change in Functioning and Health-related Quality of Life as Rated by the Medical Outcomes Survey-Version 1 (MOS-36) Bodily Pain Index (MOSBPI)
Time Frame: Mean Change from Baseline to Post-Intervention Endpoint
|
Mean change in scores on the Medical Outcomes Survey-Version 1 (MOS-36) Bodily Pain Index (MOSBPI) from baseline to post-intervention across treatment group.
Minimum Score = 0 (more); Maximum Score = 100 (less).
Positive Mean Change scores indicate improvement (an increase in scale score/less pain).
|
Mean Change from Baseline to Post-Intervention Endpoint
|
Collaborators and Investigators
Investigators
- Principal Investigator: Benoit H Mulsant, MD, University of Pittsburgh
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- R21AT001218-01A1 (U.S. NIH Grant/Contract)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Depressive Disorder
-
York UniversityCentre for Addiction and Mental HealthSuspendedDisorder, Major DepressiveCanada
-
Shalvata Mental Health CenterUnknownMAjor Depressive DisorderIsrael
-
Wyeth is now a wholly owned subsidiary of PfizerCompletedDepressive Disorder, Major Depressive DisorderUnited States
-
Samsung Medical CenterUnknownMajor Depressive Disorder, Anxiety DisorderKorea, Republic of
-
Seasons Biotechnology (Taizhou) Co., Ltd.CompletedMajor Depressive Disorder (MDD)India
-
Repurposed Therapeutics, Inc.Unknown
-
GlaxoSmithKlineCompletedMajor Depressive Disorder (MDD)United States
-
Seasons Biotechnology (Taizhou) Co., Ltd.CompletedMajor Depressive Disorder (MDDIndia
-
Gangnam Severance HospitalCompletedMajor Depressive Disorder(MDD)Korea, Republic of
-
University College, LondonCompletedUnipolar Major Depressive DisorderUnited Kingdom
Clinical Trials on Electroacupuncture
-
The Second Affiliated Hospital, Guangzhou University...RecruitingDisorder of Consciousness | ElectroacupunctureChina
-
University of California, IrvineRecruiting
-
Guang'anmen Hospital of China Academy of Chinese...Shenzhen Second People's Hospital; Shaanxi Hospital of Traditional Chinese... and other collaboratorsUnknown
-
Cancer Institute and Hospital, Chinese Academy...Unknown
-
Tianjin Nankai HospitalRecruitingSepsis | Electroacupuncture | Sepsis-associated Brain InjuryChina
-
Cancer Institute and Hospital, Chinese Academy...UnknownAcupuncture | Gastrointestinal FunctionChina
-
Corporacion Parc TauliCompletedFatigue | Inflammatory Bowel DiseaseSpain
-
Guang'anmen Hospital of China Academy of Chinese...Not yet recruitingDysmenorrhea | Adenomyosis | ElectroacupunctureChina
-
Guang'anmen Hospital of China Academy of Chinese...RecruitingChronic Urinary RetentionChina
-
Guang'anmen Hospital of China Academy of Chinese...Ministry of Science and Technology of the People´s Republic of ChinaCompletedMenopausal SyndromeChina